Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
about
Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2Antiplatelet and anticoagulant therapy in elective percutaneous coronary interventionThe refined 1.9-Å X-ray crystal structure of d-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationshipsClot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitorsEmerging anticoagulant and thrombolytic drugs.Bivalirudin utilization in cardiac surgery: shifting anticoagulation from indirect to direct thrombin inhibition.The treatment of myocardial infarction.Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coliSucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor IIImportance of factor Xa in determining the procoagulant activity of whole-blood clots.Prevention and treatment of thromboembolic and ischemic complications associated with endovascular procedures: Part I--Pathophysiological and pharmacological features.New combinational assay using soluble fibrin and d-dimer determinations: a promising strategy for identifying patients with suspected venous thromboembolism.Ximelagatran: the first oral direct thrombin inhibitor.Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinFluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.Crystal structure of the complex between thrombin and the central "E" region of fibrin.Serpins in thrombosis, hemostasis and fibrinolysisAntithrombotic effects of synthetic peptides targeting various functional domains of thrombinTissue factor in coagulation: Which? Where? When?Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis.Hydrogels for in vivo-like three-dimensional cellular studies.Bioinspired Hydrogels to Engineer Cancer Microenvironments.The nature of the stable blood clot procoagulant activities.High-affinity RNA ligands to human alpha-thrombin.New antithrombotic strategies for resistant thrombotic processes.Thrombin in inflammation and healing: relevance to rheumatoid arthritis.Glycosaminoglycans and the regulation of blood coagulation.Pharmacologic prevention of acute ischemic complications of coronary angioplasty.New antithrombotics for the treatment of acute and chronic arterial ischemia.Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.Binding of alpha-thrombin to fibrin depends on the quality of the fibrin network.Binding of human alpha-thrombin to platelet GpIb: energetics and functional effects.Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen.The effect of cyanosis on active clotting time during diagnostic catheterization.The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.Fibrinogen gamma' chain binds thrombin exosite II.Antithrombotic agents in the treatment of severe sepsis.Polyurethane modified with an antithrombin-heparin complex via polyethylene oxide linker/spacers: influence of PEO molecular weight and PEO-ATH bond on catalytic and direct anticoagulant functions.Probing the Dynamics of Clot-Bound Thrombin at Venous Shear Rates.
P2860
Q24309484-0B7F4A5D-001E-44F1-9258-FC3F92A6C020Q24793199-4F4865FB-A4F6-4C93-8435-3448AAB8EF30Q27642041-61F46731-C73B-46F0-83A0-3956F7C03030Q28294390-44E7C2BE-AAE4-4798-A061-5FD67CC91B36Q33367019-94420F15-71B5-405E-84B1-30DCC29C5C3DQ33393161-67814BA9-67D7-467D-B699-31412E806038Q33571600-33CFB1FC-6A22-4BFB-B693-B7D45472B535Q33645142-05119E56-15A4-44BF-BB55-BBD80BDC8D82Q33707130-EE2A9AE3-BACE-43E3-8B7D-4A5A72D36E93Q33897911-A0F55284-EFCD-4826-8A71-898432DF7AF6Q33931454-B9D8495A-F326-4F67-B817-58232739B851Q35130258-244B39A5-891A-4212-8B03-77307E3A1659Q35753482-EE3A139A-B070-4A60-89B3-47B6D6A259DAQ35956473-A9DA1DE3-BEC0-410D-BD01-63B5F0A45AE1Q36042279-FC127D23-B133-4374-AC7D-BAA513A44DF3Q36288526-2B393F41-3D82-4FA5-BEF0-6F7197075DE7Q36851953-0B81D694-F456-428C-8A95-6F0D6101F219Q36884340-518E7D02-D46D-444B-9F33-BE35389800EDQ37090907-D455324E-E7DC-4277-A063-D26992E4AC27Q37438302-B2C88A11-E45F-4DD5-81AF-D0E313766FBAQ37624589-D0389D5A-C3E4-4A1A-A81F-D8F5EC737814Q38012087-139977AD-92E1-4F35-838E-BD5246E4B6CEQ39386471-9E444B9B-DB46-4F7A-AC06-277B2E8025B5Q39646902-083F5C0D-A0F6-4AD9-BB4F-4D061E1AD148Q40400495-2C55B3BE-6D61-4A21-8135-28273D735EDCQ40727618-2C107271-850A-4FAE-AFDF-2CB9B7250780Q40815910-4598E899-731B-498E-BA63-B0A2EB447168Q40851193-5DCF488E-04D5-4175-B3E5-BD7BD5A32316Q41641521-D8F909A0-3292-4881-8560-83D0872BB195Q41740356-77FD6466-F15F-4B4A-963F-EFD5237673E9Q41821669-B735917C-F7AD-4804-8122-A57FD52993F0Q41909182-09603043-D077-4393-80BC-843D5B550D12Q41918902-E17B7CDE-3B50-4EE9-BE3F-4206B2D47D86Q42666355-F0DE8CFC-38B5-40A4-8352-A984531EE0F5Q42910739-92A2DED3-1303-44DA-BD21-E1F8EE7081C0Q44518890-BB87E6D4-24E6-4347-A3C3-726610F6BE78Q44518940-78814B77-3B3B-484F-9ED9-7BD4ABE2958DQ46576624-98E8F240-E403-40B6-930C-52519B6CA734Q47307641-4A78B546-A862-4B5A-8412-50B75321E249Q47870941-A6093D4C-3C06-4B01-9B3E-E8D2E971E5BE
P2860
Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@ast
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@en
type
label
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@ast
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@en
prefLabel
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@ast
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@en
P2860
P356
P1476
Fibrin monomer protects thromb ...... ications for heparin efficacy.
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.10.3619
P407
P577
1989-05-01T00:00:00Z